H. Lee Moffitt Cancer Center & Research Institute

Physician, Faculty, and Staff

Jonathan S. Zager, MD

Jonathan S. Zager, MD

Faculty Rank:

Assistant Member

Titles:

Department/Program Affiliations:

  • Comprehensive Melanoma Research Center  
  • Experimental Therapeutics  
  • Cutaneous Oncology  
  • Sarcoma  

Primary Address:

H. Lee Moffitt Cancer Center &
Research Institute
12902 Magnolia Drive
Tampa, FL 33612

Consultation/Referral Phone:

(813) 745-1085

USF Affiliations/College Department:

  • Medicine / Oncologic Sciences
  • Medicine / Surgery

University Academic Rank:

Assistant Professor

For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Jonathan S. Zager, MD

Education & Training:

  • M.D., Sackler School of Medicine - New York State American Program, 1997
  • Internship, North Shore University Hospital - New York School of Medicine, 1999 - Department of Surgery
  • Research Fellowship, Memorial-Sloan Kettering Cancer Center, 2001 - Hepatobiliary Oncology Laboratory
  • Residency, Montefiore Medical Center - Albert Einstein College of Medicine, 2004 - Department of Surgery
  • Fellowship, University of Texas, M.D. Anderson Cancer Center, 2006 - Surgical Oncology
  • Fellowship, University of Texas, M.D. Anderson Cancer Center, 2006 - Administrative Fellow

General Board Certification / SubSpecialty:

  • Surgery

For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Jonathan S. Zager, MD

Research Interests:

Research interests are in treating cutaneous melanoma as well as non melanoma skin cancers and soft tissue sarcomas including, extremity, cutaneous and retroperitoneal sarcomas. He has a particular interest in minimally invasive regionally therapy such as isolated limb infusions (ILI) for extremity in transit or recurrent melanoma. ILI’s for limb threatening unresectable sarcomas as well as percutaneous hepatic perfusions for unresectable metastatic melanoma to the liver.  He has also developed an interest in intraoperative PET probe directed surgery for difficult to localize metastatic lesions.

 



For corrections, please e-mail a request

Printer friendly version
Printer friendly version (including publications)

Jonathan S. Zager, MD

Publications:

  1. Chu CK, Zager JS, Marzban SS, Gimbel MI, Murray DR, Hestley AC, Messina JL, Sondak VK, Carlson GW, Delman KA. Routine biopsy of cloquet's node is of limited value in sentinel node positive melanoma patients. J Surg Oncol. 2010 Sep;102(4):315-320. Pubmedid: 20740592.   Pubmed ID: 20740592

  2. Farma JM, Ammori JB, Zager JS, Marzban SS, Bui MM, Bichakjian CK, Johnson TM, Lowe L, Sabel MS, Wong SL, Letson GD, Messina JL, Cimmino VM, Sondak VK. Dermatofibrosarcoma protuberans: how wide should we resect?. Ann Surg Oncol. 2010 Aug;17(8):2112-2118. Pubmedid: 20354798.   Pubmed ID: 20354798

  3. Gonzalez RJ, Padhya TA, Cherpelis BS, Prince MD, Aya-Ay ML, Sondak VK, Cruse CW, Zager JS. The surgical management of primary and metastatic Merkel cell carcinoma. Curr Probl Cancer. 2010 Jan-Feb;34(1):77-96. Pubmedid: 20371076.   Pubmed ID: 20371076

  4. McCardle TW, Sondak VK, Zager J, Messina JL. Merkel cell carcinoma: pathologic findings and prognostic factors. Curr Probl Cancer. 2010 Jan-Feb;34(1):47-64. Pubmedid: 20371074.   Pubmed ID: 20371074

  5. Santillan AA, Messina JL, Marzban SS, Crespo G, Sondak VK, Zager JS. Pathology review of thin melanoma and melanoma in situ in a multidisciplinary melanoma clinic: impact on treatment decisions. J Clin Oncol. 2010 Jan;28(3):481-486. Pubmedid: 20008627.   Pubmed ID: 20008627

  6. Santillan AA, Zager JS. Isolated limb infusion for melanoma: a less morbid alternative to hyperthermic isolated limb perfusion in the US. Expert Opin Drug Metab Toxicol. 2010 Sep;6(9):1033-1037. Pubmedid: 20078252.   Pubmed ID: 20078252

  7. Sarnaik AA, Zager JS, Cox LE, Ochoa TM, Messina JL, Sondak VK. Routine Omission of Sentinel Lymph Node Biopsy for Merkel Cell Carcinoma <= 1 cm Is Not Justified. J Clin Oncol. 2010 Jan;28(1):e7-e7. Pubmedid: 19933899.   Pubmed ID: 19933899

  8. Sondak VK, Zager JS. Who is to blame for false-negative sentinel node biopsies in melanoma?. Ann Surg Oncol. 2010 Mar;17(3):670-673. Pubmedid: 19953329. Pmcid: PMC2820671.   Pubmed ID: 19953329

  9. Zager JS, Delman KA. Commentary on pharmacotherapy of regional melanoma therapy. Expert Opin Pharmacother. 2010 Jan;11(1):1-3. Pubmedid: 20001424.   Pubmed ID: 20001424

  10. Beasley GM, Caudle A, Petersen RP, McMahon NS, Padussis J, Mosca PJ, Zager JS, Hochwald SN, Grobmyer SR, Delman KA, Andtbacka RH, Noyes RD, Kane JM, Seigler H, Pruitt SK, Ross MI, Tyler DS. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg. 2009 May;208(5):706-715. Pubmedid: 19476821.   Pubmed ID: 19476821

  11. Moller MG, Pappas-Politis E, Zager JS, Santiago LA, Yu D, Prakash A, Kinal A, Clark GS, Zhu W, Puleo CA, Glass LF, Messina JL, Sondak VK, Cruse CW. Surgical management of melanoma-in-situ using a staged marginal and central excision technique. Ann Surg Oncol. 2009 Jun;16(6):1526-1536. Pubmedid: 19050971.   Pubmed ID: 19050971

  12. Phan GQ, Messina JL, Sondak VK, Zager JS. Sentinel lymph node biopsy for melanoma: indications and rationale. Cancer Control. 2009 Jul;16(3):234-239. Pubmedid: 19556963.   Pubmed ID: 19556963

  13. Santillan AA, Delman KA, Beasley GM, Mosca PJ, Hochwald SN, Grobmyer SR, Andtbacka RH, Noyes RD, Kane JM, Ross MI, Tyler DS, Zager JS. Predictive Factors of Regional Toxicity and Serum Creatine Phosphokinase Levels After Isolated Limb Infusion for Melanoma: A Multi-Institutional Analysis. Ann Surg Oncol. 2009 Sep;16(9):2570-2578. Pubmedid: 19543771.   Pubmed ID: 19543771

  14. Sarnaik AA, Puleo CA, Zager JS, Sondak VK. Limiting the morbidity of inguinal lymphadenectomy for metastatic melanoma. Cancer Control. 2009 Jul;16(3):240-247. Pubmedid: 19556964.   Pubmed ID: 19556964

  15. Zager JS, Weber JS. Melanoma: promising new discoveries and treatment modalities for difficult clinical scenarios - part II. Cancer Control. 2009 Jul;16(3):196-197. Pubmedid: 19556959.   Pubmed ID: 19556959

  16. Ettinger DS, Agulnik M, Cristea M, Eaton K, Fidias PM, Gockerman JP, Hameed O, Handorf C, Harris EI, Jacobs CD, Javle M, Khushalani NI, Kvols L, Lenzi R, Lewis NL, Rashid A, Saltz L, Shulman LN, Zager JS, Zhen W. Occult primary. J Natl Compr Canc Netw. 2008 Nov;6(10):1026-1060. Pubmedid: 19176200.   Pubmed ID: 19176200

  17. Gimbel M, Delman K, Zager J. Therapy for unresectable recurrent and in-transit extremity melanoma. Cancer Control. 2008 Jul;15(3):225-232. Pubmedid: 18596674.   Pubmed ID: 18596674

  18. Lewis J, Zager J, Yu D, Pelaez D, Riker A, Dessureault S, Cruse C, Reintgen D, Puleo C, Sondak V. Full-Thickness Grafts Procured from Skin Overlying the Sentinel Lymph Node Basin; Reconstruction of Primary Cutaneous Malignancy Excision Defects. Ann Surg Oncol. 2008 Jun;15(6):1733-1740. Pubmedid: 18379848.   Pubmed ID: 18379848

  19. McLoughlin J, Zager J, Sondak V, Berk L. Treatment options for limited or symptomatic metastatic melanoma. Cancer Control. 2008 Jul;15(3):239-247. Pubmedid: 18596676.   Pubmed ID: 18596676

  20. Melis M, Zager J, Sondak V. Multimodality management of desmoid tumors: how important is a negative surgical margin. J Surg Oncol. 2008 Dec;98(8):594-602. Pubmedid: 19072851.   Pubmed ID: 19072851

  21. Moller M, Lewis J, Dessureault S, Zager J. Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma. Int J Hyperthermia. 2008 May;24(3):275-289. Pubmedid: 18393005.   Pubmed ID: 18393005

  22. Zager J, Bui M, Farma J, Messina J, Sondak V. Proper margins of excision in dermatofibrosarcoma protuberans: wide or narrow?. Ann Surg Oncol. 2008 Sep;15(9):2614-2616. Pubmedid: 18452044.   Pubmed ID: 18452044

  23. Zager J, Daud A. Melanoma: promising new discoveries and treatment modalities for difficult clinical scenarios. Cancer Control. 2008 Jul;15(3):192-194. Pubmedid: 18596670.   Pubmed ID: 18596670

  24. Gannon C, Zager J, Chang G, Feig B, Wood C, Skibber J, Rodriguez-BigasMA. Pelvic exenteration affords safe and durable treatment for locally advanced rectal carcinoma. Ann Surg Oncol. 2007 Jun;14(6):1870-1877. Pubmedid: 17406945.   Pubmed ID: 17406945

  25. Malhotra S, Kim T, Zager J, Bennett J, Ebright M, D'Angelica M, Fong Y. Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas. Surgery. 2007 Apr;141(4):520-529. Pubmedid: 17383529.   Pubmed ID: 17383529

  26. McLoughlin J, Zager J, Sondak V. Cytoreductive surgery for melanoma. Surg Oncol Clin N Am. 2007 Jul;16(3):683-693. Pubmedid: 17606201.   Pubmed ID: 17606201

  27. Sarnaik AA, Zager JS, Sondak VK. Multidisciplinary management of special melanoma situations: oligometastatic disease and bulky nodal sites. Curr Oncol Rep. 2007 Sep;9(5):417-427. Pubmedid: 17706171.   Pubmed ID: 17706171

  28. Sondak V, Zager J, Messina J, Thomas J. Sentinel lymph node biopsy as the standard of care for cutaneous melanoma. Clin Adv Hematol Oncol. 2007 Jun;5(6):483-490. Pubmedid: 17679922.   Pubmed ID: 17679922

  29. Jarnagin W, Zager J, Hezel M, Stanziale S, Adusumilli P, Gonen M, EbrightMI, Culliford A, Gusani N, Fong Y. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy. Cancer Gene Ther. 2006 Mar;13(3):326-334. Pubmedid: 16138120.   Pubmed ID: 16138120

  30. Khakpour N, Zager J, Yen T, Stephens T, Kuerer H, Singletary E, Ross M, Hunt K, Babiera G. The role of ultrasound in the surgical management of patients diagnosed with ductal carcinoma in situ of the breast. Breast J. 2006 May;12(3):212-215. Pubmedid: 16684318.   Pubmed ID: 16684318

  31. Lin Y, Deavers M, Sasan F, Zager J, Ramondetta L. Clinical challenges presented by three simultaneous solid tumors. Gynecol Oncol. 2006 Dec;103(3):1159-1163. Pubmedid: 17055558.   Pubmed ID: 17055558

  32. Kaleya R, Heckman J, Most M, Zager J. Lymphatic mapping and sentinel node biopsy: a surgical perspective. Semin Nucl Med. 2005 Apr;35(2):129-134. Pubmedid: 15765375.   Pubmed ID: 15765375

  33. Bocker J, Vasile J, Zager J, Goodman E. Intussusception: an uncommon cause of postoperative small bowel obstruction after gastric bypass. Obes Surg. 2004 Jan;14(1):116-119. Pubmedid: 14980045.   Pubmed ID: 14980045

  34. Delman K, Zager J, Bhargava A, Petrowsky H, Malhotra S, Ebright M, BennettJJ, Gusani N, Kooby D, Roberts G, Fong Y. Effect of murine liver cell proliferation on herpes viral behavior: implications for oncolytic viral therapy. Hepatology. 2004 Jun;39(6):1525-1532. Pubmedid: 15185293.   Pubmed ID: 15185293

  35. Jarnagin W, Zager J, Klimstra D, Delman K, Malhotra S, Ebright M, LittleS, DeRubertis B, Stanziale S, Hezel M, Federoff H, Fong Y. Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects againstrecurrence-after resection. Cancer Gene Ther. 2003 Mar;10(3):215-223. Pubmedid: 12637943.   Pubmed ID: 12637943

  36. Zager J, Delman K, Ebright M, Malhotra S, Larson S, Fong Y. Use of radiolabelled iododeoxyuridine as adjuvant treatment for experimental tumours of the liver. Br J Surg. 2003 Oct;90(10):1225-1231. Pubmedid: 14515291.   Pubmed ID: 14515291

  37. Zager J, Ohki T, Simon J, Gruber B, Zoe H, Teperman S, Stone ME J, VeithFJ, Simon R. Endovascular repair of a traumatic pseudoaneurysm of the thoracic aorta in a patient with concomitant intracranial and intra-abdominal injuries. J Trauma. 2003 Oct;55(4):778-781. Pubmedid: 14566138.   Pubmed ID: 14566138

  38. Bennett J, Delman K, Burt B, Mariotti A, Malhotra S, Zager J, Petrowsky H, Mastorides S, Federoff H, Fong Y. Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther. 2002 Nov;9(11):935-945. Pubmedid: 12386832.   Pubmed ID: 12386832

  39. Delman KA, Zager JS, Bennett JJ, Malhotra S, Ebright MI, McAuliffe PF, Halterman MW, Federoff HJ, Fong Y. Efficacy of multiagent herpes simplex virus amplicon-mediated immunotherapy as adjuvant treatment for experimental hepatic cancer. Ann Surg. 2002 Sep;236(3):337-342. Pubmedid: 12192320.   Pubmed ID: 12192320

  40. Ebright M, Zager J, Malhotra S, Delman K, Weigel T, Rusch V, Fong Y. Replication-competent herpes virus NV1020 as direct treatment of pleural cancer in a rat model. J Thorac Cardiovasc Surg. 2002 Jul;124(1):123-129. Pubmedid: 12091817.   Pubmed ID: 12091817

  41. Stanziale S, Petrowsky H, Joe J, Roberts G, Zager J, Gusani N, Ben-PoratL, Gonen M, Fong Y. Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplexvirus G207 by up regulating ribonucleotide reductase. Surgery. 2002 Aug;132(2):353-359. Pubmedid: 12219034.   Pubmed ID: 12219034

  42. Bennett J, Malhotra S, Wong R, Delman K, Zager J, St-Louis M, Johnson P, Fong Y. Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer. Ann Surg. 2001 Jun;233(6):819-826. Pubmedid: 11371740.   Pubmed ID: 11371740

  43. Paris F, Grassme H, Cremesti A, Zager J, Fong Y, Haimovitz-Friedman A, Fuks Z, Gulbins E, Kolesnick R. Natural ceramide reverses Fas resistance of acid sphingomyelinase(-/-) hepatocytes. J Biol Chem. 2001 Mar;276(11):8297-8305. Pubmedid: 11096096.   Pubmed ID: 11096096

  44. Zager J, Delman K, Malhotra S, Ebright M, Bennett J, Kates T, Halterman M, Federoff H, Fong Y. Combination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancer. Mol Med. 2001 Aug;7(8):561-568. Pubmedid: 11591892.   Pubmed ID: 11591892

  45. Zager J, Gusani N, Derubertis B, Shaw J, Kaufman J, DeNoto G. Laparoscopic appendectomy for Crohn's disease of the appendix presenting as acute appendicitis. J Laparoendosc Adv Surg Tech A. 2001 Aug;11(4):255-258. Pubmedid: 11569518.   Pubmed ID: 11569518

  46. Zager J, Shaw J, Kaufman J, DeNoto G. Three cases of small bowel intussusception in relation to a rare lesion :inflammatory fibrous polyps. Dig Surg. 2001 Aug;18(2):142-146. Pubmedid: 11351161.   Pubmed ID: 11351161

  47. Cohen M, Greenwald M, Garbus J, Zager J. Granular cell tumor--a unique neoplasm of the internal anal sphincter: report of a case. Dis Colon Rectum. 2000 Oct;43(10):1444-1446. Pubmedid: 11052524.   Pubmed ID: 11052524

  48. Delman K, Bennett J, Zager J, Burt B, McAuliffe P, Petrowsky H, Kooby D, Hawkins W, Horsburgh B, Johnson P, Fong Y. Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. Hum Gene Ther. 2000 Dec;11(18):2465-2472. Pubmedid: 11119418.   Pubmed ID: 11119418

  49. Jarnagin W, Delman K, Kooby D, Mastorides S, Zager J, Brennan M, BlumgartLH, Federoff H, Fong Y. Neoadjuvant interleukin-12 immunogene therapy protects against cancer recurrence after liver resection in an animal model. Ann Surg. 2000 May;231(5):762-771. Pubmedid: 10767798.   Pubmed ID: 10767798

  50. Zager J, Garbus J, Shaw J, Cohen M, Garber S. Jejunal diverticulosis: a rare entity with multiple presentations, a series of cases. Dig Surg. 2000 Jul;17(6):643-645. Pubmedid: 11155015.   Pubmed ID: 11155015

  51. Zager JS, Brodsky S, Berman CG. Imaging of Merkel cell carcinoma. Curr Probl Cancer. 34(1):65-76. Pubmedid: 20371075.   Pubmed ID: 20371075

Jonathan S. Zager, MD

Below is a list of active grants where the faculty member is the Principal Investigator. Grants are sorted by sponsor and then sorted by start date, with the more recent grant shown first.

Systemic ADH-1 in Combination with Normothermic Isolated Limb Infusion of Melphalan
Sponsor: Adherex Technologies, Inc.
Project Dates: April 29, 2009 to April 28, 2011
Earned to Date: $35,500

Randomized Treatment with OncoVEX GM-CSF Compared to SubQ GM-CSF Melanoma
Sponsor: BioVex, Inc.
Project Dates: August 26, 2009 to August 25, 2011
Earned to Date: $11,500

Random Assignment Study of Hepatic Artrial Infusion of Melphalan with Venous Filtration via perip
Sponsor: Delcath Systems, Inc.
Project Dates: February 4, 2008 to February 28, 2011
Annual Direct Cost: $175,200
Annual Total Cost: $227,760
Project Total: $523,460

Phase III Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection in Pts with Cutaneous Melanoma
Sponsor: John Wayne Cancer Institute
Project Dates: October 1, 2004 to September 30, 2010
Annual Direct Cost: $23,760
Annual Total Cost: $29,700
Project Total: $179,674

Neoadjuvant Geev (Imatinib Mesylate) in Dermatofibrosarcoma Protuberans
Sponsor: SARC
Project Dates: October 25, 2007 to October 24, 2010
Annual Direct Cost: $678
Annual Total Cost: $881
Project Total: $3,981

Phase II Trial of Lovastatin Linden Derm Study

2006-1761
Sponsor: Univ of California - Irvine / NCI
Project Dates: September 30, 2006 to September 29, 2010
Annual Direct Cost: $39,533
Annual Total Cost: $58,815
Project Total: $99,992

Physician/Faculty  Contact Form

© Copyright 1996 - 2010 H. Lee Moffitt Cancer Center & Research Institute